Status:
ACTIVE_NOT_RECRUITING
Acute Changes in Endothelial Function in Germ Cell Tumor Patients Treated With Cisplatin and Untreated Germ Cell Tumor Controls
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Conditions:
Germ Cell Cancer
Eligibility:
MALE
18+ years
Brief Summary
Cisplatin is one of the most common chemotherapy drugs used to treat many different cancers, including germ cell tumors (GCT). Cisplatin is very effective in treating GCT, but there are side effects. ...
Eligibility Criteria
Inclusion
- Cisplatin-Based Chemotherapy Group
- Histologically-proven diagnosis of GCT
- Male
- Age ≥18
- No prior exposure to chemotherapy or radiation
- Planned to receive 3-4 cycles of cisplatin-based chemotherapy
- Surgery-Only Group
- Histologically-proven diagnosis of GCT Male
- Age ≥18
- Surgical management of GCT performed less than 90 days before start of study (includes orchiectomy and primary retroperitoneal lymph node dissection (RPLND))
- No prior exposure to chemotherapy or radiation
Exclusion
- Cisplatin-Based Chemotherapy Group
- Prior exposure to chemotherapy or radiation
- Known diagnosis or history of being diagnosed with vasculitis, autonomic dysfunction, coronary artery disease, or collagen-vascular disease
- Surgery-Only Group
- Prior exposure to chemotherapy or radiation
- Planned for non-surgical management with chemotherapy or radiation.
- Known diagnosis or history of being diagnosed with vasculitis, autonomic dysfunction, coronary artery disease, or collagen-vascular disease.
Key Trial Info
Start Date :
October 11 2011
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2026
Estimated Enrollment :
44 Patients enrolled
Trial Details
Trial ID
NCT01453660
Start Date
October 11 2011
End Date
October 1 2026
Last Update
November 10 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065